Bristol-Myers Squibb Company Asset Resilience Ratio
Bristol-Myers Squibb Company asset resilience ratio. Bristol-Myers Squibb Company (BMY) has an Asset Resilience Ratio of 2.68% as of June 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See Bristol-Myers Squibb Company (BMY) defensive interval to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Bristol-Myers Squibb Company (1999–2025)
Asset resilience ratio of Bristol-Myers Squibb Company from 1999 to 2025. This chart shows how Bristol-Myers Squibb Company's Asset Resilience Ratio has changed over time. Read debt load of Bristol-Myers Squibb Company for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Bristol-Myers Squibb Company's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see BMY total asset value.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $2.35 Billion | 2.68% |
| Total Liquid Assets | $2.35 Billion | 2.68% |
Asset Resilience Insights
- Limited Liquidity: Bristol-Myers Squibb Company maintains only 2.68% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Bristol-Myers Squibb Company Industry Peers by Asset Resilience Ratio
Compare Bristol-Myers Squibb Company's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Merck & Company Inc
NYSE:MRK |
Drug Manufacturers - General | 0.22% |
|
AstraZeneca PLC
NASDAQ:AZN |
Drug Manufacturers - General | 0.10% |
|
Pfizer Inc
SA:PFIZ34 |
Drug Manufacturers - General | 5.33% |
|
Cosmo Pharmaceuticals N.V
F:C43 |
Drug Manufacturers - General | 10.92% |
|
Zhejiang Int'L Group Co Ltd
SHE:000411 |
Drug Manufacturers - General | 0.00% |
|
Eli Lilly and Company
SA:LILY34 |
Drug Manufacturers - General | 6.46% |
|
Dimed S.A. Distribuidora de Medicamentos
SA:PNVL3 |
Drug Manufacturers - General | 6.34% |
|
Zhangzhou Pientzehuang Pharmaceutical Co Ltd
SHG:600436 |
Drug Manufacturers - General | 17.40% |
Bristol-Myers Squibb Company Asset Resilience Ratio by Year (1999–2025)
Bristol-Myers Squibb Company asset resilience ratio by year from 1999 to 2025. The table below shows the annual Asset Resilience Ratio data for Bristol-Myers Squibb Company.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 11.85% | $10.67 Billion | $90.04 Billion | +0.13pp |
| 2024-12-31 | 11.73% | $10.86 Billion | $92.60 Billion | -1.18pp |
| 2023-12-31 | 12.90% | $12.28 Billion | $95.16 Billion | +3.35pp |
| 2022-12-31 | 9.56% | $9.25 Billion | $96.82 Billion | -6.20pp |
| 2021-12-31 | 15.75% | $17.22 Billion | $109.31 Billion | +1.87pp |
| 2020-12-31 | 13.88% | $16.45 Billion | $118.48 Billion | +2.04pp |
| 2019-12-31 | 11.85% | $15.39 Billion | $129.94 Billion | -13.19pp |
| 2018-12-31 | 25.04% | $8.76 Billion | $34.99 Billion | +4.73pp |
| 2017-12-31 | 20.30% | $6.81 Billion | $33.55 Billion | +1.46pp |
| 2016-12-31 | 18.84% | $6.35 Billion | $33.71 Billion | +12.90pp |
| 2015-12-31 | 5.94% | $1.89 Billion | $31.75 Billion | +0.41pp |
| 2014-12-31 | 5.52% | $1.86 Billion | $33.75 Billion | +3.09pp |
| 2013-12-31 | 2.43% | $939.00 Million | $38.59 Billion | -0.83pp |
| 2012-12-31 | 3.27% | $1.17 Billion | $35.90 Billion | -5.70pp |
| 2011-12-31 | 8.97% | $2.96 Billion | $32.97 Billion | +1.67pp |
| 2010-12-31 | 7.30% | $2.27 Billion | $31.08 Billion | +4.62pp |
| 2009-12-31 | 2.68% | $831.00 Million | $31.01 Billion | +1.70pp |
| 2008-12-31 | 0.98% | $289.00 Million | $29.49 Billion | -0.64pp |
| 2007-12-31 | 1.62% | $424.00 Million | $26.17 Billion | -6.18pp |
| 2006-12-31 | 7.80% | $2.00 Billion | $25.57 Billion | -1.97pp |
| 2005-12-31 | 9.77% | $2.75 Billion | $28.14 Billion | -2.70pp |
| 2004-12-31 | 12.47% | $3.79 Billion | $30.43 Billion | +1.49pp |
| 2003-12-31 | 10.98% | $3.01 Billion | $27.45 Billion | +4.49pp |
| 2002-12-31 | 6.48% | $1.62 Billion | $25.02 Billion | +5.91pp |
| 2001-12-31 | 0.57% | $154.00 Million | $27.06 Billion | -0.59pp |
| 2000-12-31 | 1.15% | $203.00 Million | $17.58 Billion | -0.23pp |
| 1999-12-31 | 1.38% | $237.00 Million | $17.11 Billion | -- |
About Bristol-Myers Squibb Company
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. The company offers products for oncology, hematology, immunology, cardiovascular, and neuroscience indications. Its products include Opdivo for anti-cancer indications; Opdivo Qvantig, a subcutaneous PD-1 inhibitor for solid tumors; Orencia for active rhe… Read more